Participated · Series C · May 2018

Akili Interactive develops prescription digital therapeutics, including EndeavorRx, the first-and-only FDA‑cleared treatment delivered through a video game experience for children with ADHD. EndeavorRx is built on Akili’s Selective Stimulus Management Engine (SSME) and uses adaptive algorithms to target attentional control systems. The company plans to scale go-to-market efforts to bring EndeavorRx to families and healthcare professionals, expand its global footprint in ADHD and beyond, and advance a pipeline of prescription digital therapeutics for chronic and acute cognitive disorders. Akili emphasizes clinical validation, citing positive results in prospective randomized, controlled trials and extensive clinical studies. Financially, the company announced $160M in combined equity and debt financing—$110M Series D equity and a credit facility of up to $50M with Silicon Valley Bank—and reports total equity funding to date of $230M. The funding is intended to support commercialization, technology development, clinical research, and international expansion. Akili develops prescription digital medicines that embed targeted stimuli into immersive action video game experiences to treat conditions across neurology and psychiatry. Its lead program, AKL-T01 for pediatric ADHD, is under FDA review following positive pivotal study topline results announced in December 2017. If cleared, AKL-T01 would be the first prescription video game to treat a medical condition and the first prescription digital medicine for children with ADHD. The company has additional programs in Major Depressive Disorder, multiple sclerosis and various inflammatory diseases, and expects results from a Phase 2 MDD study and an MS pilot by the end of 2018. Akili is also developing complementary clinical monitors and measurement-based care applications. The company was founded by PureTech Health and is advancing its platform with recent equity financing. Akili Interactive develops prescription digital treatments that deliver therapeutic activity through action video game experiences. The company is building a broad pipeline of programs on its patented technology platform to treat cognitive deficits and symptoms across neurology and psychiatry, including ADHD, major depressive disorder, autism spectrum disorder and various inflammatory diseases. Its lead candidate is AKL‑T01 and it is also developing complementary clinical monitors and measurement‑based care applications. Akili was founded by PureTech Health and is led by CEO Eddie Martucci, Ph.D. The company used the financing to advance digital treatment candidates through regulatory milestones, prepare for commercial launch, and to broaden its product pipeline, including programs in depression and multiple sclerosis. Akili builds clinically validated cognitive treatments and assessments delivered through an action video‑game interface, based on its Project: EVO platform licensed from Dr. Adam Gazzaley at UCSF. The company is clinical‑stage and is conducting a pivotal STARS‑ADHD trial of Project: EVO in pediatric ADHD with plans to seek FDA approval if results are favorable. Akili has multiple clinical studies across ADHD, autism spectrum disorder, depression, Alzheimer’s disease, and traumatic brain injury, and has expanded into neurodegeneration indications including Parkinson’s disease, major depressive disorder, and multiple sclerosis. The platform is designed to target core neurological processing and can adapt difficulty in real time for remote use without physician calibration. Akili plans to use the new funds to support and expand clinical development into new areas, increase focus on neurodegeneration, and build out its commercial infrastructure as it nears market with late‑stage products. The company was founded by PureTech Health together with neuroscientists and game designers and has strategic partnerships with Pfizer and Autism Speaks and investment from Shire PLC. Akili develops mobile software-based treatments and monitors designed to function as action video games, targeting cognitive disorders with adaptive, medical-grade software. Its lead product candidate, Project: EVO, is licensed from Dr. Adam Gazzaley's lab at UCSF and was previously published as a Nature cover story. The platform targets cognitive interference processing and adapts difficulty in real time to allow wide-ranging ability levels to use the product without physician calibration or extra hardware. Akili is conducting multiple clinical trials across pediatric ADHD, autism spectrum disorder (in collaboration with Autism Speaks), depression, Alzheimer’s disease (in collaboration with Pfizer) and traumatic brain injury. A recent open-label pilot in pediatric ADHD showed improvements in attention, inhibition and working memory, and the company plans a large randomized pivotal study with results expected in 2017. The company announced $30.5 million in new equity investments to support further clinical development and to build commercial infrastructure toward potential FDA clearance and a planned product launch in 2017.

Participated · Series C · May 2018

Akili is a Boston-based digital medicine company that develops software-based therapeutic products to treat cognitive dysfunction. Its pipeline targets conditions including ADHD, multiple sclerosis, and depression. The company is focused on digital-medicine interventions rather than traditional pharmaceuticals. Financially, Akili completed a $55M Series C funding round announced in May 2018. The Series C was led by Temasek and included participation from Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies. The financing reflects institutional investor support for the company’s ongoing development efforts. Akili is a digital medicine company developing clinically validated, non-pharmacological therapeutics and diagnostics for cognitive disorders delivered in an action video game interface. Its lead product platform, Project: EVO, licensed from Dr. Adam Gazzaley's lab at UCSF, targets the neurological ability to process multiple streams of information and adapts difficulty in real time. The intervention aims to improve attention, working memory, and other executive functions, while the monitoring product may enable screening and disease tracking across neurological and psychiatric disorders. Akili is conducting multiple clinical trials, including a pivotal STARS-ADHD trial of Project: EVO in pediatric ADHD, and studies in autism, depression, Alzheimer's disease, traumatic brain injury, Parkinson's disease, and multiple sclerosis. The company plans to expand clinical development into neurodegeneration and to build out commercial infrastructure as it nears market with late-stage products. Financially, Akili announced an $11.9 million expansion of its recent Series B, bringing total Series B proceeds to $42.4 million, with new investments from M Ventures and Amgen Ventures and prior backers including Pfizer and Shire.